CLINICAL TRIALS
Clinical Trials
We are focused on finding innovative solutions to unmet medical needs. We have completed enrollment in our second Phase III Study for CM-AT in Autism, The Blüm™ Study.
Learn More
CLINICAL TRIALS
AUTISM
Autism
We’re working to bring a first-in-class Autism treatment to market. We believe this treatment has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered, and learn more about our novel approach.
Learn More
ABOUT US
About Us
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological and other disorders. Our pipeline includes our lead drug candidate, CM-AT, for Autism, along with a number of therapies for other neurological conditions.
Learn more about how our research helps patients.
Learn More
Technology
Technology
We are developing breakthrough technologies that shed light on key connections that factor into neurological diseases. We’ve found a critical link to the role of the pancreas in these conditions, and are approaching treatment with a revolutionary method of drug delivery.
Learn more
OUR STORY
Our Story
What started as one doctor’s observation has expanded into a broad array of treatments that may significantly affect neurological diseases. We have performed important research, made discoveries and are disrupting conventional thinking. Learn more about our story.
Learn More
Pipeline
Pipeline
At Curemark, we are working towards a product pipeline that brings breakthrough medical discoveries to the patients who need them the most.
Learn More
CONTACT US
Contact Us
We put the patient first, in everything we do. Get the latest updates on our company, products, clinical trials and more.
Learn More
News
CLINICAL TRIALS
Clinical Trials
We are focused on finding innovative solutions to unmet medical needs. We have completed enrollment in our second Phase III Study for CM-AT in Autism, The Blüm™ Study.
Learn More
AUTISM
Autism
We’re working to bring a first-in-class Autism treatment to market. We believe this treatment has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered, and learn more about our novel approach.
Learn More
ABOUT US
About Us
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological and other disorders. Our pipeline includes our lead drug candidate, CM-AT, for Autism, along with a number of therapies for other neurological conditions.
Learn more about how our research helps patients.
Learn More
Technology
Technology
We are developing breakthrough technologies that shed light on key connections that factor into neurological diseases. We’ve found a critical link to the role of the pancreas in these conditions, and are approaching treatment with a revolutionary method of drug delivery.
Learn more
OUR STORY
Our Story
What started as one doctor’s observation has expanded into a broad array of treatments that may significantly affect neurological diseases. We have performed important research, made discoveries and are disrupting conventional thinking. Learn more about our story.
Learn More
Pipeline
Pipeline
At Curemark, we are working towards a product pipeline that brings breakthrough medical discoveries to the patients who need them the most.
Learn More
CONTACT US
Contact Us
We put the patient first, in everything we do. Get the latest updates on our company, products, clinical trials and more.
Learn More
News